Phaseline

Targets › UBA1

UBA1 (Ubiquitin-like modifier-activating enzyme 1): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology, Hematology; next expected readout Apr 2027.

Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system. Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP. Essential for the formation of radiation-induced foci, timely DNA repair…. (UniProt, P22314)

Open in Phaseline: the race on UBA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)TAK-243
Ubiquitin-activating enzyme (UAE) inhibitor
UBA1Phase 1Advanced Lymphoma; Myelodysplastic Syndrome With Excess BlastsApr 2027
University of California, San DiegoSB-4826
Small ubiquitin-like modifier E1 inhibitor
UBA1Phase 1Non Hodgkin LymphomaFeb 2031

Conditions

Advanced Lymphoma (1) Myelodysplastic Syndrome With Excess Blasts (1) Non Hodgkin Lymphoma (1)

Modalities

small molecule (1), mixed (1)

Companies

National Cancer Institute (NCI) (1) University of California, San Diego (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.